Selective pressure as an essential force in molecular evolution of myeloid leukemic clones: A view from the window of Fanconi anemia

Leukemia

Volumn 13, Issue 11, 1999, Pages 1784-1789

  Lensch, M W ^a   Rathbun, R K ^a   Olson, S B ^a,b   Jones, G R ^a,b   Bagby Jr , G C ^a,b,c,d  

^a Dept of Molecular and Med Genetics ^*  (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d Hatfield Research Center   (United States)

Author keywords

Acute myeloid leukemia; Clonal evolution; Cytogenetics; Fanconi anemia; Molecular evolution; Myelodysplasia

Indexed keywords

ALKYLATING AGENT; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW CELL; CANCER INHIBITION; CELL CLONE; CELL PROLIFERATION; CELL SELECTION; CHILDHOOD CANCER; CHROMOSOME DELETION; ENVIRONMENTAL FACTOR; FANCONI ANEMIA; GENE FUNCTION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; MOUSE; MYELODYSPLASIA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032722653     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401586     Document Type: Review

References (63)

1. Anderson RL, Bagby GC. The prognostic value of chromosome studies in patients with the preleukemic syndrome (hemopoietic dysplasia). Leukemia Res 1982; 6: 175-181.
2. Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, DeVita VT. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988; 71: 403-414.
3. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76: 1083-1091.
4. Ruddon RW. Tumor suppressor genes. Cancer Biology, 3rd edn. Oxford University Press: New York, 1995, pp 318-340.
5. Hesketh R. Tumor suppressor genes. The Oncogene and Tumor Suppressor Gene Factsbook, 2nd edn. Academic Press: London, 1997, pp 26-30.
6. Nowell PC. Chromosome abnormalities in myelodysplastic syndromes. Semin Oncol 1992; 19: 25-33.
7. Li C, Suardet L, Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 1995; 270: 4971-4974.
8. Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M, Koeffler HP. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995; 86: 1924-1930.
9. Whitney MA, Royle G, Low MJ, Kelly MA, Axthelm ML, Reifsteck C, Olson S, Braun RE, Heinrich MC, Rathbun RK, Bagby GC, Grompe M. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 1996; 88: 49-58.
10. Rathbun RK, Faulkner GR, Ostroski MH, Christianson TA, Hughes G, Jones G, Cahn R, Maziarz R, Royle G, Keeble W, Heinrich MC, Grompe M, Tower PA, Bagby GC. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 1997; 90: 974-985.
11. Haneline LS, Broxmeyer HE, Cooper S, Hangoc G, Carreau M, Buchwald M, Clapp DW. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/-mice. Blood 1998; 91: 4092-4098.
12. Morley A, Blake J. An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan. Blood 1974; 44: 49-56.
13. Auerbach AD, Adler B, O'Reilly RJ, Kirkpatrick D, Chaganti RS. Effect of procarbazine and cyclophosphamide on chromosome breakage in Fanconi anemia cells: relevance to bone marrow transplantation. Cancer Genet Cytogenet 1983; 9: 25-36.
14. Kwee ML, Poll EH, van de Kamp JJ, de Koning H, Eriksson AW, Joenje H. Unusual response to bifunctional alkylating agents in a case of Fanconi anaemia. Hum Genet 1983; 64: 384-387.
15. Fanconi G. Familial constitutional panmyelocytopathy, Fanconi's anemia (FA) I. Clinical aspects. Semin Hematol 1967; 4: 233-240.
16. Alter BP. Fanconi's anemia and malignancies. Am J Hematol 1996; 53: 99-110.
17. Alter BP. Leukemia and preleukemia in Fanconi's anemia. Cancer Genet Cytogenet 1992; 58: 206-208.
18. Alter BP, Tenner MS. Brain tumors in patients with Fanconi's anemia. Arch Pediatr Adolesc Med 1994; 148: 661-663.
19. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cylogenet 1991 ; 51: 1-12.
20. Kupfer GM, Naf D, D'Andrea AD. Molecular biology of Fanconi anemia. Hematol Oncol Clin North Am 1997; 11: 1045-1060.
21. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, Lightfoot J, Carreau M, Callen DF, Savoia A, Cheng NC, van Berkel CG, Strunk MH, Gille JJ, Pals G, Kruyt FA, Pronk JC, Arwert F, Buchwald M, Joenje H. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996; 14: 320-323.
22. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation (published erratum appears in Nature 1992; 358: 434). Nature 1992; 356: 763-767.
23. de Winter JP, Waisfisz Q, Rooimans MA, van Berkel CG, Bosnoyan-Collins L, Alon N, Carreau M, Bender O, Demuth I, Schindler D, Pronk JC, Arwert F, Hoehn H, Digweed M, Buchwald M, Joenje H. The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nat Genet 1998; 20: 281-283.
24. Haneline LS, Gobbett TA, Ramani R, Carreau M, Buchwald M, Yoder MC, Clapp DW. Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood 1999; 94: 1-8.
25. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol 1995; 91: 245-252.
26. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
27. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
28. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932-10937.
29. Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H, Tsujimoto Y. Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis (published erratum appears in Cancer Res 1996; 56: 3152). Cancer Res 1996; 56: 1713-1718.
30. Maciejewski I, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by Interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183-3190.
31. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995; 86: 883-889.
32. Rathbun RK, Christianson TA, Jones G, Keeble W, Bagby GC. The hypersensitivity of Fanconi anemia progenitor cells to interferon-gamma involves the activation of caspases 3 and 8 but not caspase 1. Exp Hematol 1998; 26: 724.
33. Wang J, Otsuki T, Youssoufian H, Foe JL, Kim S, Devetten M, Yu J, Li Y, Dunn D, Liu JM. Overexpression of the Fanconi anemia group C gene (FAC) protects hematopoietic progenitors from death induced by Fas-mediated apoptosis. Cancer Res 1998; 58: 3538-3541.
34. Berger R, Jonveaux P. Clonal chromosomal abnormalities in Fanconi anemia. Hematol Cell Ther 1996; 38: 291-296.
35. Davies SM, Khan S, Wagner JE, Arthur DC, Auerbach AD, Ramsay NKC, Wesidorf DJ. Unrelated donor bone marrow transplantation for Fanconi anemia. Bone Marrow Transplant 1996; 17: 43-47.
36. Huret JL, Tanzer J, Guilhot F, Frocrain-Herchkovitch C, Savage JRK. Karyotype evolution in the bone marrow of a patient with Fanconi anemia: breakpoints in clonal anomalies of this disease. Cytogenet Cell Genet 1988; 48: 224-227.
37. Maarek O, Jonveaux P, LeConiat M, Derre J, Berger R. Fanconi anemia and bone marrow clonal chromosome abnormalities. Leukemia 1996; 10: 1700-1704.
38. Stivrins TJ, Davis RB, Sanger W, Fritz J, Purtilo DT. Transformation of Fanconi's anemia to acute nonlymphocytic leukemia associated with emergence of monosomy 7. Blood 1984; 64: 173-176.
39. Russo CL, Zwerdling T. Letter to the Editor: Recognition of Fanconi's anemia eight years following treatment for acute nonlymphocytic leukemia. Am J Hematol 1992; 40: 78-79.
40. Barton JC, Parmley RT, Carroll AJ, Huang ST, Goodnough LT, Findley HW Jr, Ragab AH. Preleukemia in Fanconi's anemia: hematopoietic cell multinuclearity, membrane duplication, and dysgranulogenesis. J Submicrosc Cytol 1987; 19: 355-364.
41. Standen GR, Hughes IA, Geddes AD, Jones BM, Wardrop CAJ. Myelodysplastic syndrome with trisomy 8 in an adolescent with Fanconi anemia and selective IgA deficiency. Am J Hematol 1989; 31: 280-283.
42. Lo Ten Foe JR, Kwee ML, Rooimans MA, Oostra AB, Veerman AJ, van Weel M, Pauli RM, Shahidi NT, Dokal I, Roberts I, Altay C, Gluckman E, Gibson RA, Mathew CG, Arwert F, Joenje H. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet 1997; 5: 137-148.
43. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF, Taniguchi T. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968-971.
44. Knudson AC Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
45. Asimakopoulos FA, White NJ, Nacheva E, Green AR. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 1994; 84: 3086-3094.
46. Lessard M, Herry A, Berthou C, Léglise MC, Abgrall JF, Morice P, Flandrin G. FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes. Leukemia Res 1998; 22: 303-312.
47. Knapp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985; 60: 507-516.
48. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas MD Anderson Cancer Center experience. J Clin Oncol 1996; 14: 2722-2730.
49. Berger R, LeConiat M, Schaison C. Chromosome abnormalities in bone marrow of Fanconi anemia patients. Cancer Genet Cytogenet 1993; 65: 47-50.
50. Appelbaum FR, Le Beau MM, Willman CL. Secondary leukemia. White Cells, Hematology. American Society of Hematology: Washington, DC, 1996, pp 33-47.
51. Itoh S, Harada H, Nakamura Y, White R, Taniguchi T. Assignment of the human interferon regulatory factor-1 (IRF1) gene to chromosome 5q23-q31. Genomics 1991; 10: 1097-1099.
52. Sato T, Selleri C, Young NS, Maciejewski JP. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-γ due to phosphorylation of Stat1 and Stat3. Blood 1997; 90: 4749-4758.
53. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993; 259: 971-974.
54. Fagerlie S, Diaz J, Faulkner G, Grompe M, Keeble W, Tower P, Christianson T, Bagby GC. The Fanconi anemia group C protein is necessary for normal STAT-1 phosphorylation. Blood 1997; 90: 571A.
55. Taniguchi T, Lamphier MS, Tanaka N. IRF-1 : the transcription factor linking the interferon response and oncogenesis. Biochim Biophys Acta 1997; 1333: M9-M17.
56. Boultwood J, Fidler C, Lewis S, MacCarthy A, Sheridan H, Kelley S, Oscier D, Buckle VJ, Wainscoat JS. Allelic loss of lrf-1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q-chromosome in some patients with the 5q-syndrome. Blood 1993; 82: 2611-2616.
57. Kroef MJ, Bolk MW, Willemze R. Landegent JE. Absence of loss of heterozygosity of the lrf-1 gene in some patients with a 5q31 deletion. Blood 1994; 83: 2382-2386.
58. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, Lamphier MS, Hirai H, Taniguchi T. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism ot tumor suppressor inactivation. Oncogene 1994; 9: 3313-3320.
59. Beretta L, Gabbay M, Berger R, Hanash SM, Sonenberg N. Expression of the protein kinase PKR is modulated by IRF-1 and is reduced in 5q-associated leukemias. Oncogene 1996; 12: 1593-1596.
60. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
61. Koury MJ, Home DW, Brown ZA, Pietenpol JA, Blount BC, Ames BN. Hard R, Koury ST. Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. Blood 1997; 89: 4617-4623.
62. Irvine AE, Magill MK, Somerville LE, McMullin MF. Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia. Exp Hematol 1998; 26: 435-439.
63. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S, Preisler H. A paradigm shift in myelodysplastic syndromes. Leukemia 1996; 10: 1648-1652.